Robert E. Landry - EVP Finance CFO at Regeneron Pharmaceuticals, Inc.

Insider Transactions and Holdings

Class	Num Shares	Value	Price $	Transaction Date	Ownership	Underlying Class
Common Stock	23.7K	$22.7M	$956.65	Feb 2, 2024	Direct
Common Stock	270	$252K	$934.71	Feb 2, 2024	By 401(k) Plan
Non-Qualified Stock Option (right to buy)	11.8K			Feb 2, 2024	Direct	Common Stock

Showing 1 to 3 of 3 entries

Sym	Class	Transaction	%	Value $	* Price $	Shares	Shares After	Date	Ownership

* An asterisk sign (*) next to the price indicates that the price is likely invalid.